These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 18974139

  • 1. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
    Fournier PG, Daubiné F, Lundy MW, Rogers MJ, Ebetino FH, Clézardin P.
    Cancer Res; 2008 Nov 01; 68(21):8945-53. PubMed ID: 18974139
    [Abstract] [Full Text] [Related]

  • 2. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T.
    Cancer Res; 1995 Aug 15; 55(16):3551-7. PubMed ID: 7627963
    [Abstract] [Full Text] [Related]

  • 3. How do bisphosphonates inhibit bone metastasis in vivo?
    Fournier PG, Stresing V, Ebetino FH, Clézardin P.
    Neoplasia; 2010 Jul 15; 12(7):571-8. PubMed ID: 20651986
    [Abstract] [Full Text] [Related]

  • 4. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
    Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, Clézardin P.
    Cancer Res; 2007 Oct 15; 67(20):9894-902. PubMed ID: 17942921
    [Abstract] [Full Text] [Related]

  • 5. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
    Stresing V, Fournier PG, Bellahcène A, Benzaïd I, Mönkkönen H, Colombel M, Ebetino FH, Castronovo V, Clézardin P.
    Bone; 2011 Feb 15; 48(2):259-66. PubMed ID: 20920623
    [Abstract] [Full Text] [Related]

  • 6. Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790.
    Hald A, Hansen RR, Thomsen MW, Ding M, Croucher PI, Gallagher O, Ebetino FH, Kassem M, Heegaard AM.
    Int J Cancer; 2009 Sep 01; 125(5):1177-85. PubMed ID: 19444917
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system.
    Hall DG, Stoica G.
    J Bone Miner Res; 1994 Feb 01; 9(2):221-30. PubMed ID: 8140935
    [Abstract] [Full Text] [Related]

  • 9. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention.
    Lipton A.
    J Support Oncol; 2004 Feb 01; 2(3):205-13; discussion 213-4, 216-7, 219-20. PubMed ID: 15328823
    [Abstract] [Full Text] [Related]

  • 10. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.
    Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clément-Lacroix P, Clézardin P.
    Cancer Res; 2007 Jun 15; 67(12):5821-30. PubMed ID: 17575150
    [Abstract] [Full Text] [Related]

  • 11. Antitumor effects of bisphosphonates.
    Green JR.
    Cancer; 2003 Feb 01; 97(3 Suppl):840-7. PubMed ID: 12548584
    [Abstract] [Full Text] [Related]

  • 12. Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease.
    van Beek ER, Lowik CW, van Wijngaarden J, Ebetino FH, Papapoulos SE.
    Breast Cancer Res Treat; 2009 Nov 01; 118(2):307-13. PubMed ID: 18989771
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
    Murayama T, Kawasoe Y, Yamashita Y, Ueno Y, Minami S, Yokouchi M, Komiya S.
    Anticancer Res; 2008 Nov 01; 28(4B):2147-54. PubMed ID: 18751388
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
    Green JR.
    Acta Oncol; 2005 Nov 01; 44(3):282-92. PubMed ID: 16076701
    [Abstract] [Full Text] [Related]

  • 18. Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption.
    Alvarez E, Westmore M, Galvin RJ, Clapp CL, Considine EL, Smith SJ, Keyes K, Iversen PW, Delafuente DM, Sulaimon S, Zambrano C, Ma L, Sato M, Martin TJ, Teicher BA, Galbreath EJ.
    Clin Cancer Res; 2003 Nov 15; 9(15):5705-13. PubMed ID: 14654555
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonates for the prevention of bone metastases.
    Coleman RE.
    Semin Oncol; 2002 Dec 15; 29(6 Suppl 21):43-9. PubMed ID: 12584694
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.